NCT03010228 - Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis | Biotech Hunter

Enrollment

179

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

September 28, 2017

Study Completion Date

January 16, 2019

Conditions

Lyme Borreliosis, Nervous System

Interventions

BIOLOGICAL

VLA15 with Alum

I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses

BIOLOGICAL

VLA15 without Alum

I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses

Trial Locations (5)

University Hospital Ghent, Ghent

Celerion Inc., Lincoln

Celerion, Inc, Lincoln

eStudy Site, La Mesa

eStudySite, La Mesa